When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IPSEY - Revance files U.S. application for frown line treatment; shares up 3% premarket
Ipsen SA ADR
Revance Therapeutics (NASDAQ:RVNC) has filed a marketing application in the U.S. seeking approval of DAXI (daxibotulinumtoxinA for injection) for the treatment of moderate-to-severe glabellar (frown) lines. The agency's action date is November 25.
More news on: Revance Therapeutics, Inc., Allergan plc, Nestle S.A. ADR, Healthcare stocks news,